Key result
Cardioband transcatheter annuloplasty significantly reduces tricuspid regurgitation severity at 12 months with ~6% mortality.
Why the study?
The study aimed to evaluate the clinical and echocardiographic outcomes of transcatheter tricuspid annuloplasty using the Cardioband system in high-risk patients with severe functional tricuspid regurgitation.
Does transcatheter tricuspid annuloplasty using the Cardioband system reduce tricuspid regurgitation severity and improve clinical outcomes in high-risk patients with severe functional tricuspid regurgitation?
Cohort (n=64)
No
Does transcatheter tricuspid annuloplasty using the Cardioband system reduce tricuspid regurgitation severity and improve clinical outcomes in high-risk patients with severe functional tricuspid regurgitation?
Transcatheter tricuspid annuloplasty with the Cardioband system was associated with reduced tricuspid regurgitation severity and a 6.3% mortality rate at 12 months in high-risk patients, though findings are limited by the single-center observational design and procedural complication risk.
Answers are grounded in this paper and cite their sources.
Low 12-month mortality supports procedural feasibility in high-risk TR; leaves open comparative efficacy versus medical therapy in randomized trials.
OBJECTIVE: To evaluate the clinical and echocardiographic outcomes of transcatheter tricuspid annuloplasty using the Cardioband system in a single-center cohort of high-risk patients with severe functional tricuspid regurgitation. METHODS: This single-center prospective cohort study included 64 consecutive patients with severe functional tricuspid regurgitation undergoing transcatheter tricuspid annuloplasty with the Cardioband system. Clinical and echocardiographic data were collected at baseline, discharge, 6-months, and 12-months. Primary endpoints included changes in tricuspid regurgitation severity, annular dimensions, and clinical status, as well as all-cause mortality and heart failure hospitalization. Outcomes were analyzed using available-case data. RESULTS: At 12-months, among patients with available echocardiographic data (n = 44), tricuspid regurgitation severity was reduced compared with baseline (p < 0.001); 15.9% had trace or mild TR, 45.5% had moderate TR, 27.3% had severe TR, and 11.4% had massive or torrential TR. All-cause mortality at 12-months was 6.3% (4/64 patients). According to TVARC criteria, intraprocedural success was achieved in 81.3% of patients, while a more stringent definition yielded a success rate of 65.6%. CONCLUSION: In this single-center cohort of high-risk patients with severe functional tricuspid regurgitation, transcatheter tricuspid annuloplasty using the Cardioband system was associated with reductions in tricuspid regurgitation severity and improvements in selected clinical parameters at 12-months. However, these findings should be interpreted with caution given the observational design, incomplete follow-up, and the absence of a control group, as well as the observed rate of procedural complications. Further studies, ideally including larger multicenter cohorts and controlled comparisons, are needed to better define the role of this therapy in the management of tricuspid regurgitation.
No takes yet. Share an insight, caveat, or question.
Mussons et al. (2026) conducted a cohort in Severe functional tricuspid regurgitation (n=64). Transcatheter tricuspid annuloplasty with the Cardioband system was evaluated on Changes in tricuspid regurgitation severity, annular dimensions, and clinical status, as well as all-cause mortality and heart failure hospitalization at 12 months (p=<0.001). Transcatheter tricuspid annuloplasty with Cardioband reduced tricuspid regurgitation severity at 12 months (p<0.001), with 6.3% all-cause mortality and 81.3% intraprocedural success.
Synapse has enriched 10 related papers. Consider them for comparative context: